Abbott experimental sound wave trial meets primary goals for heart disease
An investigational sound wave system for severely calcified coronary artery disease successfully met both primary endpoints in a clinical trial of 335 patients.
FTMQ Health, written by our newsroom0 views
Abbott announced that its investigational SonicForce coronary calcium treatment system met both primary endpoints in a clinical trial, Stock Titan reported. The TECTONIC trial evaluated 335 human patients across 40 sites in the United States who suffered from severely calcified coronary artery disease. Scans revealed heart artery calcium fractures after receiving the sound wave treatment. [1]
The study demonstrated a 97 percent procedural success rate among participants, according to Stock Titan. The 30 day target lesion failure rate was recorded at 0.3 percent. SonicForce remains an investigational device limited to experimental use. [1]
The heart is a muscular organ that pumps blood through blood vessels throughout the body. Together, the heart and blood vessels form the circulatory system, delivering oxygen and nutrients to tissues while removing metabolic waste. [2]
As FTMQ Health reported earlier, researchers are also exploring other catheter based procedures for heart related conditions. Henry Ford Health initiated a trial in August 2026 evaluating pulmonary artery denervation to help patients with pulmonary hypertension stemming from heart disease. [3]
In short
- Abbott's investigational SonicForce system met both primary endpoints in the TECTONIC trial.
- The trial enrolled 335 patients with severely calcified coronary artery disease across 40 U.S. sites.
- The 30-day target lesion failure rate was 0.3 percent and procedural success reached 97 percent.
- SonicForce remains restricted to investigational use.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Scans found heart-artery calcium fractures after an investigational sound-wave treatmentStock Titan, 4h ago (the report this story comes from)
Background
- [2]Heart on Wikipedia
- [3]Henry Ford Health Begins Trial for Pulmonary Artery Denervation Treatment FTMQ Health, 9d ago
Our newsroom writes these reports with the help of software, from the 3 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Teleflex completes patient enrollment for European coronary scaffold studyMedical Science, 7d ago
- Henry Ford Health Begins Trial for Pulmonary Artery Denervation TreatmentMedical Science, 9d ago
- Ear nerve stimulation shows promise for severe high blood pressureFitness, 8d ago
- Combining procedures improves stent expansion in Mount Sinai heart trialMedical Science, 1h ago
- Moderna and Merck melanoma vaccine clinical trial data released earlyTop Stories, 9d ago
More in Medical Science
- Mindfulness therapy alters brain responses to opioid cues in new study1h ago
- NHS trial tests five day radiotherapy course for breast cancer1h ago
- Combining procedures improves stent expansion in Mount Sinai heart trial1h ago
- Walmart and Care Access Plan Three New Clinical Trial Centers2d ago
- Trial evaluates one week intradermal rabies vaccine regimen in adult trial3d ago
- Planned power shutoffs during wildfires increase respiratory emergency visits5d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.
Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.